{"gene":"RET","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1987,"finding":"The RET transforming gene encodes a fusion protein with a carboxy-terminal domain homologous to tyrosine kinases (40-50% homology), preceded by a hydrophobic transmembrane domain sequence, establishing RET as a transmembrane receptor tyrosine kinase.","method":"cDNA cloning and sequencing of ret transforming gene","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing and structural characterization, foundational paper replicated across decades","pmids":["3037315"],"is_preprint":false},{"year":1995,"finding":"MEN2A mutations in extracellular cysteine residues of RET result in constitutive RET dimerization and ligand-independent kinase activation, while the MEN2B mutation (M918T in the kinase domain) activates RET kinase constitutively without covalent dimerization but alters catalytic properties both quantitatively and qualitatively. Both convert RET into a dominant transforming gene in NIH 3T3 cells.","method":"NIH 3T3 transformation assay, biochemical analysis of RET dimerization and kinase activity, mutagenesis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, mutagenesis, transformation assay; replicated by multiple labs (PMID 8570194)","pmids":["7824936","8570194"],"is_preprint":false},{"year":1996,"finding":"GDNF signals through the Ret receptor tyrosine kinase: a Xenopus embryo bioassay demonstrated GDNF activates Ret, and explant cultures from Ret-deficient mouse embryos showed that normal Ret function is necessary for GDNF signaling in the peripheral nervous system, establishing Ret as a functional receptor for GDNF essential for kidney organogenesis and peripheral nervous system development.","method":"Xenopus embryo bioassay, Ret-knockout mouse explant cultures","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function (Ret-KO) combined with bioassay, replicated across multiple labs","pmids":["8657282"],"is_preprint":false},{"year":1997,"finding":"TrnR2 (GFRα2) is a GPI-anchored co-receptor that mediates both neurturin and GDNF signaling through Ret. Fibroblasts expressing TrnR2 and Ret are ~30-fold more sensitive to neurturin than to GDNF, whereas TrnR1 (GFRα1)-Ret complexes respond equivalently to both, establishing that distinct GFRα-Ret complexes confer differential ligand selectivity.","method":"Receptor reconstitution in fibroblasts, cell-based signaling assay, expression analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution experiment with quantitative ligand sensitivity measurements, clear mechanistic distinction between co-receptor complexes","pmids":["9182803"],"is_preprint":false},{"year":1997,"finding":"FMTC mutations E768D and V804L in the RET kinase domain are gain-of-function mutations that confer autophosphorylation and transforming activity selectively to the RET51 long isoform (1114 aa) but not to the RET9 short isoform, demonstrating isoform-specific oncogenic activation and providing a biochemical basis for phenotype restriction to thyroid C-cells.","method":"Site-directed mutagenesis, autophosphorylation assay, Rat1 fibroblast transformation assay, PC12 neuronal differentiation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with multiple functional readouts (transformation, autophosphorylation, differentiation), clear isoform comparison","pmids":["9242375"],"is_preprint":false},{"year":1999,"finding":"Ret stimulation activates c-Src kinase, and Ret associates with the SH2 domain of Src in a phosphotyrosine-dependent manner. Microinjection of a kinase-inactive c-Src mutant blocks Ret-mediated mitogenic effect, establishing that Src kinase activity is required for Ret-mediated mitogenesis.","method":"c-Src kinase activity assay, SH2 domain pull-down, microinjection of dominant-negative c-Src","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical interaction assay plus dominant-negative epistasis experiment, multiple orthogonal methods","pmids":["10070972"],"is_preprint":false},{"year":2000,"finding":"MEN2A-RET (Cys634) activates PI3K and its downstream effector AKT/PKB. Mutation of Tyr-1062 (docking site for Shc and p85 regulatory subunit of PI3K) abrogates PI3K/AKT activation and abolishes transforming activity. A dominant-interfering PI3K suppresses RET-MEN2A transformation, while AKT overexpression enhances it, establishing PI3K/AKT as essential for RET-mediated transformation.","method":"PI3K activity assay, AKT phosphorylation assay, site-directed mutagenesis (Y1062F), retroviral dominant-negative PI3K expression, soft agar transformation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, kinase assays, dominant-negative epistasis, and transformation assay in single study with multiple orthogonal methods","pmids":["10652352"],"is_preprint":false},{"year":2001,"finding":"MEN2A-RET activates STAT3 via two YxxV/Q STAT3 docking sites at Tyr752 and Tyr928, inducing both Tyr705 and Ser727 phosphorylation of STAT3. STAT3α (but not STAT3β) mediates enhanced proliferation and cyclin-D1 promoter activity downstream of MEN2A-RET, establishing STAT3 as a component of MEN2A-RET oncogenic signaling.","method":"Stable NIH3T3 cell lines, STAT3 phosphorylation assay, cyclin-D1 promoter reporter assay, soft agar growth assay, mutagenesis of docking sites","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based assays with reporter and phenotypic readouts, single lab with two orthogonal methods","pmids":["11536047"],"is_preprint":false},{"year":2001,"finding":"GDNF activates BMK1 (ERK5) through RET tyrosine kinase via phosphorylation of tyrosine 1062. BMK1 activation is not significantly impaired by MEK1 or PI3K inhibitors, indicating a distinct signaling pathway from Y1062. RET-MEN2A activates MEF2C transcription factor in a Y1062-dependent manner via MEK5.","method":"BMK1 kinase activation assay, Y1062F mutagenesis, pharmacological pathway inhibitors, luciferase reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis combined with pharmacological inhibitors and reporter assay, single lab","pmids":["11237712"],"is_preprint":false},{"year":2002,"finding":"Dok1 is a docking protein for RET tyrosine kinase (identified by yeast two-hybrid). Dok1 binds RET-MEN2B more strongly than RET-MEN2A. Dok1 (via Ras-GAP binding at multiple tyrosines) suppresses Ras/Erk activation by GDNF/RET-MEN2B, while Dok1 (via Nck binding at Y361) is required for JNK/c-Jun activation, establishing Dok1 as a bifunctional scaffold with opposing effects on RET downstream pathways.","method":"Yeast two-hybrid screen, site-directed mutagenesis of Dok1 tyrosines, Ras/Erk and JNK/c-Jun activation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — yeast two-hybrid identification confirmed by mutagenesis and multiple pathway assays, mechanistically detailed","pmids":["12087092"],"is_preprint":false},{"year":2004,"finding":"Dominant-negative RET(ΔTK) disrupts oncogenic RET autophosphorylation in MTC cells, abolishing downstream Akt and ERK phosphorylation, decreasing cyclin D1 expression, increasing p21 and p27, stimulating apoptosis with decreased BCL-2, reducing cell cycle progression, and suppressing tumor growth in transgenic mice with orthotopic MTC.","method":"Adenoviral dominant-negative RET expression, Western blotting of signaling proteins, cell cycle analysis, apoptosis assay, in vivo transgenic mouse tumor model","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative loss-of-function with multiple downstream pathway readouts in vitro and in vivo, multiple orthogonal methods","pmids":["15316058"],"is_preprint":false},{"year":2009,"finding":"ETS transcription factors Etv4 and Etv5 are positively regulated downstream of GDNF-Ret signaling in ureteric bud tips. Double knockout mice lacking both Etv4 alleles and one Etv5 allele show renal agenesis or severe hypodysplasia; complete double homozygous knockout causes total kidney development failure. Downstream Etv4/Etv5 targets include Cxcr4, Myb, Met, and Mmp14, establishing Etv4/Etv5 as key effectors in the Ret-dependent gene network for renal branching morphogenesis.","method":"Genetic mouse knockouts (Etv4/Etv5 compound mutants), gene expression analysis in ureteric bud","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via compound knockout mice with clear organ-level phenotype and downstream gene identification","pmids":["19898483"],"is_preprint":false},{"year":2010,"finding":"RET51 activation by GDNF or NGF triggers formation of a RET51/FKBP52 complex. Substitution of tyrosine 905 of RET51 (phosphorylated by both GDNF and NGF) disrupts this complex, establishing Y905 phosphorylation as required for RET51-FKBP52 interaction.","method":"Co-immunoprecipitation, site-directed mutagenesis (Y905 substitution), patient mutation screening","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP with mutagenesis validation, single lab, mechanistically specific","pmids":["20442138"],"is_preprint":false},{"year":2011,"finding":"Caspase cleavage of RET generates two fragments: an intracellular domain capable of triggering apoptosis, and a membrane-anchored N-terminal ectodomain (containing cadherin domains) that functions as a cadherin accessory protein, enhancing cadherin-mediated cell aggregation in sympathetic neurons. This establishes a non-canonical ligand-independent role for RET in cell adhesion regulation.","method":"Caspase cleavage assay, cell aggregation assay in sympathetic neurons, mutagenesis of caspase cleavage site","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical cleavage assay plus functional cell adhesion readout, single lab with two orthogonal approaches","pmids":["21357690"],"is_preprint":false},{"year":2012,"finding":"RET is alternatively spliced to encode isoforms (primarily RET9 and RET51) with distinct trafficking properties: RET9 accumulates in the Golgi intracellularly while RET51 is efficiently matured and present at higher levels on the plasma membrane. RET51 is internalized faster after ligand binding and undergoes recycling back to the plasma membrane. This differential trafficking produces more rapid and longer ERK/MAPK signaling from RET51 versus RET9.","method":"Subcellular fractionation, live-cell imaging, FRAP, internalization assays, ERK/MAPK signaling time-course","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal localization and trafficking methods (fractionation, live imaging, FRAP) directly linked to functional signaling differences","pmids":["22875993"],"is_preprint":false},{"year":2012,"finding":"KIF5B-RET fusion leads to aberrant constitutive activation of RET kinase and functions as an oncogenic driver in lung adenocarcinoma, as demonstrated by anchorage-independent growth of NIH3T3 cells that is suppressible by the RET tyrosine kinase inhibitor vandetanib.","method":"Whole-transcriptome sequencing to identify fusion, NIH3T3 transformation assay, RET kinase inhibitor treatment","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional transformation assay with pharmacological validation, replicated in two independent papers (PMID 22327623 and 22327624)","pmids":["22327624","22327623"],"is_preprint":false},{"year":2014,"finding":"GM1 ganglioside enhances Ret kinase activity in striatal tissue via GFRα1, increasing binding of endogenous GDNF to GFRα1. GM1-induced Ret activation leads to Tyr1062 phosphorylation and PI3K/Akt and Erk and Src signaling recruitment. Src kinase (PP1/PP2 sensitive) is required for GM1-induced Ret activation. Neutralization of released GDNF does not inhibit the Ret response, indicating GM1 acts upstream at the GFRα1 level.","method":"Striatal slice preparation, kinase activity assay, Src inhibitor treatment, GDNF neutralization, co-receptor dependence assays","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitors plus neutralization experiment in tissue preparation, single lab","pmids":["24821093"],"is_preprint":false},{"year":2015,"finding":"RET internalization occurs primarily through clathrin-coated pits (not caveolin). The AP2 μ subunit interacts directly with both RET isoforms and is required for RET internalization via clathrin-mediated endocytosis. RET51 is rapidly and robustly recruited to clathrin-coated pits upon GDNF stimulation, while RET9 recruitment is slower and less pronounced, contributing to their distinct signaling durations.","method":"TIRF microscopy, co-localization with clathrin/caveolin, AP2 interaction assay, siRNA knockdown of AP2","journal":"Traffic","confidence":"High","confidence_rationale":"Tier 2 / Strong — TIRF live imaging combined with AP2 interaction assay and functional knockdown, multiple orthogonal methods in single study","pmids":["26304132"],"is_preprint":false},{"year":2016,"finding":"RET51 isoform depletion has significantly greater effects than RET9 depletion on medullary thyroid carcinoma (MTC) cell survival, proliferation, anoikis resistance, and on papillary thyroid carcinoma (PTC) cell migration, mesenchymal marker expression, matrix metalloproteinase expression, and invasive potential, establishing RET51 as the functionally dominant isoform in thyroid carcinoma contexts.","method":"shRNA-mediated isoform-specific knockdown, cell viability assay, migration assay, invasion assay, anoikis assay, immunoblotting of EMT markers","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific KD with multiple functional readouts, single lab","pmids":["27872141"],"is_preprint":false},{"year":2016,"finding":"Drosophila models of CCDC6-RET and NCOA4-RET fusions show that both drive cell migration, delamination, and EMT, but NCOA4-RET produces more severe phenotypes than CCDC6-RET mirroring clinical behavior. A kinome/drug screen revealed CCDC6-RET and NCOA4-RET act through different signaling networks with distinct drug sensitivities, and WEE1 inhibitor plus sorafenib is synergistically specific for NCOA4-RET.","method":"Drosophila transgenic cancer model, kinome RNAi screen, drug library screen, combination drug synergy assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic screen in Drosophila model with pharmacological validation, single lab","pmids":["27626672"],"is_preprint":false},{"year":2017,"finding":"Potent RET inhibitors (AD80, ponatinib) that bind RET in the DFG-out (catalytically inactive) conformation selectively kill RET-rearranged tumor cells. Chemical genomics and phosphoproteomics identified the CCDC6-RET I788N mutation and MAPK pathway reactivation as resistance mechanisms to RET inhibitors.","method":"DFG-out conformation binding (type II inhibitors), chemical genomics screen, phosphoproteomics in RET-rearranged cells, drug sensitivity assays","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural binding mode characterization combined with phosphoproteomics and resistance mechanism identification, multiple orthogonal methods","pmids":["28615362"],"is_preprint":false},{"year":2019,"finding":"FAT4 (atypical cadherin) interacts with RET through extracellular cadherin repeats and perturbs assembly of the RET-GFRα1-GDNF signaling complex, reducing RET signaling. Loss of Fat4 in mice causes excessive RET signaling and abnormal ureteric budding; removing one copy of Gdnf rescues the Fat4-knockout kidney phenotype, establishing FAT4 as a juxtacrine negative regulator of RET signaling during kidney development.","method":"Fat4 conditional knockout mice, Gdnf genetic rescue experiment, co-immunoprecipitation of FAT4-RET interaction, kidney developmental analysis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Gdnf heterozygous rescue of Fat4 KO) plus biochemical interaction (Co-IP), multiple orthogonal methods","pmids":["30853441"],"is_preprint":false},{"year":2020,"finding":"Acquired resistance to selpercatinib (selective RET inhibitor) is driven by RET G810 solvent front mutations (G810R, G810S, G810C) that sterically hinder selpercatinib binding, as predicted by structural modeling and confirmed by in vitro kinase and cell-based assays. In addition, MET amplification and rare RET-wildtype tumor cell populations driven by alternative mitogenic drivers represent off-target resistance routes.","method":"Circulating tumor DNA analysis, post-mortem biopsy, patient-derived xenograft model of acquired resistance, enzyme assay, cell-based assay, structural modeling","journal":"Journal of thoracic oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clinical ctDNA and tissue combined with in vitro enzyme/cell assays and structural modeling; replicated in multiple patients and labs (PMID 31988000, 35304457)","pmids":["31988000","35304457"],"is_preprint":false},{"year":2023,"finding":"Vepafestinib (TAS0953/HM06) has a unique binding mode to RET with best-in-class selectivity, retains activity against RETL730, RETV804, and RETG810 on-target resistance mutations, and shows superior CNS pharmacokinetics compared to approved RET inhibitors, translating to improved tumor control in an intracranial RET-driven cancer model.","method":"In vitro RET kinase selectivity panel, cell-based assays with resistance mutants, pharmacokinetic brain penetration studies, intracranial xenograft model","journal":"Nature cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and in vivo methods in single study, single lab, novel binding mode claimed but full structural detail not described in abstract","pmids":["37743366"],"is_preprint":false},{"year":2017,"finding":"EGF/EGFR activation triggers resistance to RET inhibitors (sunitinib, E7080, vandetanib, sorafenib) in CCDC6-RET lung cancer cells by transducing bypass survival signaling through ERK and AKT. EGFR-TKI treatment resensitizes cells to RET inhibitors, establishing EGFR bypass as a mechanism of RET inhibitor resistance.","method":"Cell viability assay with RET inhibitors ± EGF, ERK/AKT phosphorylation Western blot, EGFR siRNA, EGFR-TKI combination","journal":"Yonsei medical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown and pharmacological rescue in cell lines, single lab","pmids":["27873490"],"is_preprint":false},{"year":2004,"finding":"TTF-1 (thyroid transcription factor-1) directly binds the RET promoter and activates RET transcription. HSCR-associated RET promoter SNPs overlap TTF-1 binding sites and decrease RET transcription in functional reporter assays. A TTF-1 missense mutation (Gly322Ser) in an HSCR patient compromises activation from HSCR-associated RET promoter haplotypes, establishing TTF-1 as a direct transcriptional regulator of RET.","method":"Luciferase reporter assay, TTF-1 binding site analysis, patient mutation functional characterization, chromatin context analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter reporter assay combined with patient mutation functional characterization, single lab","pmids":["15548547"],"is_preprint":false},{"year":2017,"finding":"GDNF plus GFRα1 (but not GDNF alone) promotes RET-dependent perineural invasion, proliferation, and soft agar colony formation in prostate cancer cells. Conditioned medium from dorsal root ganglia (containing secreted GFRα1) promotes these transformed phenotypes, blocked by anti-GFRα1 antibody. RET signaling activates ERK or AKT depending on context, but p70S6 kinase phosphorylation is markedly increased in all cases; p70S6K knockdown markedly decreases RET-induced transformed phenotypes.","method":"RET knockdown, anti-GFRα1 antibody, dorsal root ganglion perineural invasion assay, p70S6K siRNA, Western blotting, in vivo tumor xenograft","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown of RET and p70S6K with multiple functional readouts, in vivo xenograft, single lab","pmids":["28490466"],"is_preprint":false}],"current_model":"RET is a single-pass transmembrane receptor tyrosine kinase that requires GPI-anchored GFRα co-receptors to bind GDNF family ligands, upon which it dimerizes and trans-autophosphorylates specific intracellular tyrosines (notably Y1062) to recruit adaptor proteins (Shc, Dok1, p85-PI3K) activating RAS/ERK, PI3K/AKT, JNK, STAT3, and BMK1/ERK5 pathways; oncogenic activation occurs either through extracellular cysteine mutations (MEN2A) that force constitutive disulfide-bonded dimerization, or through kinase-domain mutations (MEN2B M918T) that alter catalytic specificity without covalent dimerization, or through chromosomal rearrangements (RET/PTC, KIF5B-RET, CCDC6-RET, NCOA4-RET) that replace the extracellular domain with dimerization-promoting partner sequences; two major C-terminal splice isoforms, RET9 and RET51, display distinct Golgi retention versus plasma membrane localization, differential clathrin/AP2-mediated internalization kinetics, and consequently different ERK/MAPK signaling durations, with RET51 being the functionally dominant isoform; acquired resistance to selective RET inhibitors (selpercatinib) is primarily driven by solvent-front mutations at G810 that sterically block inhibitor binding, and by MAPK pathway reactivation through MET amplification or alternative driver selection."},"narrative":{"mechanistic_narrative":"RET is a single-pass transmembrane receptor tyrosine kinase that transduces signals from GDNF-family ligands to control kidney organogenesis and peripheral nervous system development [PMID:3037315, PMID:8657282]. Ligand recognition is indirect: RET partners with GPI-anchored GFRα co-receptors, and the specific GFRα paralog assembled into the complex dictates ligand selectivity (GFRα1-RET responds to GDNF and neurturin equivalently, while GFRα2-RET is biased toward neurturin) [PMID:9182803]. Upon ligand engagement RET trans-autophosphorylates intracellular tyrosines that serve as docking sites for adaptor and effector proteins, most prominently Y1062, which couples RET to PI3K/AKT and to the ERK5/BMK1-MEF2C axis [PMID:10652352, PMID:11237712]; additional sites recruit STAT3 (Y752/Y928), the bifunctional Dok1 scaffold that oppositely tunes Ras/ERK versus JNK output, and FKBP52 (Y905), while RET activation also engages c-Src kinase as a required mediator of mitogenesis [PMID:10070972, PMID:11536047, PMID:12087092, PMID:20442138]. In renal development this signaling drives a branching-morphogenesis gene network through the ETS transcription factors Etv4/Etv5 and is held in check by the atypical cadherin FAT4, a juxtacrine negative regulator that perturbs RET-GFRα1-GDNF complex assembly [PMID:19898483, PMID:30853441]; RET transcription itself is directly activated by TTF-1 [PMID:15548547]. RET is alternatively spliced into RET9 and RET51 isoforms with distinct trafficking — RET9 accumulates in the Golgi whereas RET51 matures efficiently to the plasma membrane, is more rapidly recruited to clathrin/AP2-coated pits and recycled, producing faster and longer ERK/MAPK signaling, and is the functionally dominant isoform in thyroid carcinoma [PMID:22875993, PMID:26304132, PMID:27872141]. Oncogenic activation occurs through extracellular cysteine mutations (MEN2A) that force constitutive disulfide-bonded dimerization, kinase-domain mutations (MEN2B M918T) that constitutively activate and alter catalytic specificity without covalent dimerization, and chromosomal fusions (KIF5B-RET, CCDC6-RET, NCOA4-RET) that confer ligand-independent kinase activation and drive transformation, migration and EMT [PMID:7824936, PMID:8570194, PMID:22327624, PMID:22327623, PMID:27626672]. RET is essential for tumor maintenance in these contexts, and inhibition reverses oncogenic signaling and tumor growth [PMID:15316058]. Acquired resistance to selective RET inhibitors arises from G810 solvent-front mutations that sterically block drug binding and from bypass MAPK reactivation via MET amplification or EGFR signaling, motivating next-generation inhibitors that retain activity against resistance mutants [PMID:28615362, PMID:31988000, PMID:35304457, PMID:27873490, PMID:37743366]. Beyond canonical signaling, caspase cleavage generates a RET ectodomain that acts as a cadherin accessory protein promoting cell aggregation, a ligand-independent adhesion role [PMID:21357690].","teleology":[{"year":1987,"claim":"Established the molecular identity of RET as a transmembrane receptor tyrosine kinase, defining the protein class whose dysregulation underlies its oncogenic and developmental roles.","evidence":"cDNA cloning and sequencing of the ret transforming gene","pmids":["3037315"],"confidence":"High","gaps":["Did not identify the physiological ligand or co-receptor","No downstream signaling characterized"]},{"year":1996,"claim":"Identified GDNF as the activating ligand and demonstrated RET is genetically required for kidney and peripheral nervous system development, linking RET signaling to organogenesis.","evidence":"Xenopus embryo bioassay and Ret-knockout mouse explant cultures","pmids":["8657282"],"confidence":"High","gaps":["Mechanism of ligand binding (co-receptor requirement) not yet defined","Downstream effectors of developmental signaling unknown"]},{"year":1997,"claim":"Resolved how RET achieves ligand selectivity, showing that distinct GPI-anchored GFRα co-receptors set the ligand preference of the RET complex.","evidence":"Receptor reconstitution in fibroblasts with quantitative ligand sensitivity measurements","pmids":["9182803"],"confidence":"High","gaps":["Structural basis of GFRα-RET-ligand assembly not resolved","In vivo consequences of co-receptor switching not addressed"]},{"year":1995,"claim":"Defined two mechanistically distinct routes to oncogenic RET activation — extracellular cysteine mutations forcing dimerization versus a kinase-domain mutation altering catalytic specificity — explaining MEN2A versus MEN2B.","evidence":"NIH 3T3 transformation assay, dimerization and kinase activity biochemistry, mutagenesis","pmids":["7824936","8570194"],"confidence":"High","gaps":["Did not map full set of downstream effectors driving transformation","Tissue specificity of phenotypes not explained"]},{"year":1997,"claim":"Showed that oncogenic activation can be isoform-restricted, with FMTC kinase-domain mutations transforming RET51 but not RET9, providing a biochemical basis for tissue-restricted phenotypes.","evidence":"Site-directed mutagenesis with autophosphorylation, fibroblast transformation, and PC12 differentiation assays","pmids":["9242375"],"confidence":"High","gaps":["Molecular reason for differential isoform sensitivity not defined","In vivo relevance to C-cell restriction inferred but not tested"]},{"year":1999,"claim":"Identified c-Src as a required effector of RET mitogenic signaling, extending the RET pathway beyond canonical adaptor recruitment.","evidence":"Src kinase activity assay, SH2 pull-down, and dominant-negative Src microinjection","pmids":["10070972"],"confidence":"High","gaps":["Direct RET tyrosine docking site for Src not mapped","Relationship to other RET pathways not integrated"]},{"year":2000,"claim":"Pinpointed Y1062 as the docking site coupling RET to PI3K/AKT and demonstrated this axis is essential for RET-driven transformation.","evidence":"PI3K/AKT kinase assays, Y1062F mutagenesis, dominant-negative PI3K, soft agar transformation","pmids":["10652352"],"confidence":"High","gaps":["Did not separate AKT from other Y1062-dependent outputs","In vivo tumor dependence not tested in this study"]},{"year":2001,"claim":"Expanded the RET signaling map to STAT3 (via Y752/Y928) and ERK5/BMK1-MEF2C (via Y1062), defining additional proliferative and transcriptional outputs.","evidence":"Cell-line phosphorylation assays, docking-site mutagenesis, and luciferase/cyclin-D1 reporter assays","pmids":["11536047","11237712"],"confidence":"Medium","gaps":["Single-lab cell-based evidence without in vivo confirmation","Crosstalk between these parallel pathways not resolved"]},{"year":2002,"claim":"Characterized Dok1 as a bifunctional RET scaffold that simultaneously suppresses Ras/ERK and enables JNK/c-Jun, revealing how a single adaptor can balance opposing RET outputs.","evidence":"Yeast two-hybrid identification with Dok1 tyrosine mutagenesis and pathway activation assays","pmids":["12087092"],"confidence":"High","gaps":["Physiological consequences of Dok1 balancing in normal development not tested","Preferential MEN2B binding mechanism not structurally explained"]},{"year":2004,"claim":"Demonstrated that RET kinase activity is required for medullary thyroid carcinoma maintenance, validating RET as a therapeutic target in vivo.","evidence":"Adenoviral dominant-negative RET in MTC cells and transgenic orthotopic mouse tumor model with signaling, cell cycle, and apoptosis readouts","pmids":["15316058"],"confidence":"High","gaps":["Did not test small-molecule inhibition","Effector(s) most critical for survival not isolated"]},{"year":2004,"claim":"Identified TTF-1 as a direct transcriptional activator of RET and linked HSCR-associated promoter variants to reduced RET expression, connecting RET dosage to disease.","evidence":"Luciferase reporter assays, TTF-1 binding site analysis, and functional characterization of a patient TTF-1 mutation","pmids":["15548547"],"confidence":"Medium","gaps":["Single-lab reporter-based evidence","Endogenous chromatin occupancy not directly shown"]},{"year":2009,"claim":"Placed Etv4/Etv5 as essential downstream effectors of GDNF-Ret signaling in renal branching morphogenesis, identifying the transcriptional output of the developmental pathway.","evidence":"Compound Etv4/Etv5 knockout mice with ureteric bud gene expression analysis","pmids":["19898483"],"confidence":"High","gaps":["Direct versus indirect regulation of target genes not fully separated","How RET kinase output converts to Etv induction not mechanistically traced"]},{"year":2010,"claim":"Mapped a RET51-specific phosphotyrosine (Y905) required for FKBP52 recruitment, adding an isoform-selective interaction to the RET signaling repertoire.","evidence":"Co-immunoprecipitation with Y905 mutagenesis and patient mutation screening","pmids":["20442138"],"confidence":"Medium","gaps":["Single Co-IP-based interaction without reciprocal structural validation","Functional consequence of the RET51-FKBP52 complex not defined"]},{"year":2011,"claim":"Uncovered a non-canonical, ligand-independent RET function in which caspase cleavage yields an ectodomain acting as a cadherin accessory protein in cell adhesion.","evidence":"Caspase cleavage and cleavage-site mutagenesis assays with sympathetic neuron aggregation assays","pmids":["21357690"],"confidence":"Medium","gaps":["Single-lab evidence; in vivo relevance not established","Physiological trigger for caspase cleavage of RET unclear"]},{"year":2012,"claim":"Linked RET9/RET51 splice isoforms to distinct trafficking itineraries and signaling kinetics, explaining how isoform choice tunes the duration of ERK/MAPK output.","evidence":"Subcellular fractionation, live-cell imaging, FRAP, internalization assays, and ERK/MAPK time-courses","pmids":["22875993"],"confidence":"High","gaps":["Trafficking machinery not yet identified at this stage","Consequences for in vivo physiology not tested"]},{"year":2012,"claim":"Established RET gene fusion (KIF5B-RET) as an oncogenic driver in lung adenocarcinoma, extending the spectrum of RET activation beyond point mutations.","evidence":"Whole-transcriptome sequencing, NIH3T3 transformation assay, and vandetanib inhibition","pmids":["22327624","22327623"],"confidence":"High","gaps":["Did not detail downstream signaling differences from other fusions","Patient response data not addressed"]},{"year":2015,"claim":"Identified clathrin/AP2-mediated endocytosis as the route of RET internalization and showed faster RET51 recruitment to coated pits underlies isoform-specific signaling durations.","evidence":"TIRF microscopy, AP2 μ-subunit interaction assay, and AP2 siRNA knockdown","pmids":["26304132"],"confidence":"High","gaps":["Downstream sorting fate (degradation versus recycling) not fully resolved here","How endocytic rate quantitatively sets signal duration not modeled"]},{"year":2016,"claim":"Demonstrated RET51 is the functionally dominant isoform driving thyroid carcinoma survival, proliferation, migration and invasion, prioritizing it as the disease-relevant species.","evidence":"Isoform-specific shRNA knockdown with viability, migration, invasion, anoikis, and EMT-marker readouts","pmids":["27872141"],"confidence":"Medium","gaps":["Single-lab study","Mechanistic basis of isoform dominance in these phenotypes not dissected"]},{"year":2016,"claim":"Showed that different RET fusion partners (CCDC6-RET vs NCOA4-RET) signal through distinct networks with divergent drug sensitivities, revealing fusion-specific therapeutic vulnerabilities.","evidence":"Drosophila transgenic cancer models with kinome RNAi and drug-combination synergy screens","pmids":["27626672"],"confidence":"Medium","gaps":["Findings in Drosophila model require human validation","Molecular basis for partner-specific signaling networks not defined"]},{"year":2017,"claim":"Defined DFG-out (type II) inhibitor binding as an effective strategy against RET-rearranged tumors and identified MAPK reactivation and a gatekeeper-region mutation as resistance routes.","evidence":"DFG-out inhibitor characterization, chemical genomics, and phosphoproteomics in RET-rearranged cells","pmids":["28615362"],"confidence":"High","gaps":["Did not anticipate solvent-front resistance to selective inhibitors","Clinical durability of type II inhibitors not assessed"]},{"year":2017,"claim":"Established EGFR bypass signaling through ERK and AKT as a resistance mechanism to RET inhibitors that is reversible by EGFR-TKI co-treatment, defining an actionable combination strategy.","evidence":"Cell viability with RET inhibitors ± EGF, EGFR siRNA, and EGFR-TKI combination in CCDC6-RET lung cells","pmids":["27873490"],"confidence":"Medium","gaps":["Single-lab cell-line evidence","In vivo and clinical relevance of the combination not tested here"]},{"year":2017,"claim":"Showed that secreted GFRα1 enables ligand-driven RET transformation and perineural invasion in prostate cancer, with p70S6K as a convergent required effector, extending RET oncogenic biology beyond mutation/fusion.","evidence":"RET and p70S6K knockdown, anti-GFRα1 antibody, dorsal root ganglion perineural invasion assay, and xenografts","pmids":["28490466"],"confidence":"Medium","gaps":["Single-lab study","Source and regulation of tumor-microenvironment GFRα1 not fully defined"]},{"year":2019,"claim":"Identified FAT4 as a juxtacrine negative regulator that restrains RET signaling during kidney development by perturbing RET-GFRα1-GDNF complex assembly.","evidence":"Fat4 conditional knockout mice with Gdnf heterozygous genetic rescue and FAT4-RET co-immunoprecipitation","pmids":["30853441"],"confidence":"High","gaps":["Structural mechanism of FAT4 interference with complex assembly not resolved","Role outside kidney development not addressed"]},{"year":2020,"claim":"Defined the molecular basis of acquired resistance to selective RET inhibitor selpercatinib, identifying G810 solvent-front mutations and off-target MET amplification.","evidence":"ctDNA and post-mortem tissue analysis, patient-derived xenografts, kinase/cell-based assays, and structural modeling","pmids":["31988000","35304457"],"confidence":"High","gaps":["Strategies to overcome G810 mutations not provided in this study","Frequency and co-occurrence of resistance routes not fully quantified"]},{"year":2023,"claim":"Provided a next-generation RET inhibitor (vepafestinib) that retains activity against on-target resistance mutations and improves CNS penetration, addressing the resistance liabilities of prior inhibitors.","evidence":"RET kinase selectivity panel, resistance-mutant cell assays, brain-penetration pharmacokinetics, and intracranial xenograft model","pmids":["37743366"],"confidence":"Medium","gaps":["Single-study; clinical efficacy not yet established","Full structural basis of the unique binding mode not detailed"]},{"year":null,"claim":"How the diverse RET tyrosine docking codes, isoform trafficking, and fusion-partner-specific networks integrate to produce context-specific physiological versus oncogenic outcomes remains incompletely resolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking phospho-site usage to pathway selection across cell types","Predictive rules for which resistance route emerges under each inhibitor are lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,3]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[6,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[14,17]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[14]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,15,22]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[14,17]}],"complexes":["RET-GFRα1-GDNF signaling complex"],"partners":["GFRA1","GFRA2","GDNF","SRC","DOK1","FKBP52","AP2M1","FAT4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P07949","full_name":"Proto-oncogene tyrosine-protein kinase receptor Ret","aliases":["Cadherin family member 12","Proto-oncogene c-Ret"],"length_aa":1114,"mass_kda":124.3,"function":"Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation (PubMed:21994944, PubMed:23333276, PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), triggering RET autophosphorylation and activation, leading to activation of downstream signaling pathways, including the MAPK- and AKT-signaling pathways (PubMed:21994944, PubMed:23333276, PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 signaling: in the presence of the ligand GDNF in somatotrophs within pituitary, promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF (PubMed:20616503, PubMed:21994944). Required for the molecular mechanisms orchestration during intestine organogenesis via the ARTN-GFRA3 signaling: involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue (By similarity). Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed:28846097, PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner (PubMed:20702524, PubMed:21357690). Also active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage (PubMed:21357690). Triggers the differentiation of rapidly adapting (RA) mechanoreceptors (PubMed:20064382). Involved in the development of the neural crest (By similarity). Regulates nociceptor survival and size (By similarity). Phosphorylates PTK2/FAK1 (PubMed:21454698) Isoform 1 in complex with GFRAL induces higher activation of MAPK-signaling pathway than isoform 2 in complex with GFRAL","subcellular_location":"Cell membrane; Endosome membrane","url":"https://www.uniprot.org/uniprotkb/P07949/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RET","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RET","total_profiled":1310},"omim":[{"mim_id":"619706","title":"LEUCINE-RICH REPEAT NEURONAL PROTEIN 4; LRRN4","url":"https://www.omim.org/entry/619706"},{"mim_id":"619683","title":"B-BOX- AND SPRY DOMAIN-CONTAINING PROTEIN; BSPRY","url":"https://www.omim.org/entry/619683"},{"mim_id":"619400","title":"VISCERAL LEIOMYOPATHY, AFRICAN DEGENERATIVE; ADL","url":"https://www.omim.org/entry/619400"},{"mim_id":"619344","title":"PURKINJE CELL PROTEIN 2; PCP2","url":"https://www.omim.org/entry/619344"},{"mim_id":"618679","title":"GDNF FAMILY RECEPTOR ALPHA-4; GFRA4","url":"https://www.omim.org/entry/618679"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":10.9},{"tissue":"parathyroid gland","ntpm":18.7}],"url":"https://www.proteinatlas.org/search/RET"},"hgnc":{"alias_symbol":["PTC","CDHF12","RET51","CDHR16"],"prev_symbol":["HSCR1","MEN2A","MTC1","MEN2B"]},"alphafold":{"accession":"P07949","domains":[{"cath_id":"2.60.40.60","chopping":"28-262","consensus_level":"medium","plddt":88.1831,"start":28,"end":262},{"cath_id":"2.60.40","chopping":"272-396","consensus_level":"medium","plddt":88.9928,"start":272,"end":396},{"cath_id":"2.60.40.60","chopping":"406-504","consensus_level":"medium","plddt":91.5149,"start":406,"end":504},{"cath_id":"-","chopping":"524-620","consensus_level":"high","plddt":93.1182,"start":524,"end":620},{"cath_id":"3.30.200.20","chopping":"711-804","consensus_level":"high","plddt":89.1131,"start":711,"end":804},{"cath_id":"1.10.510.10","chopping":"811-822_844-902_911-1013","consensus_level":"high","plddt":88.2306,"start":811,"end":1013}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P07949","model_url":"https://alphafold.ebi.ac.uk/files/AF-P07949-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P07949-F1-predicted_aligned_error_v6.png","plddt_mean":78.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RET","jax_strain_url":"https://www.jax.org/strain/search?query=RET"},"sequence":{"accession":"P07949","fasta_url":"https://rest.uniprot.org/uniprotkb/P07949.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P07949/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P07949"}},"corpus_meta":[{"pmid":"22327623","id":"PMC_22327623","title":"RET, ROS1 and ALK fusions in lung cancer.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22327623","citation_count":1068,"is_preprint":false},{"pmid":"7824936","id":"PMC_7824936","title":"Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7824936","citation_count":727,"is_preprint":false},{"pmid":"8657282","id":"PMC_8657282","title":"GDNF signalling through the Ret receptor tyrosine kinase.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8657282","citation_count":711,"is_preprint":false},{"pmid":"22327624","id":"PMC_22327624","title":"KIF5B-RET fusions in lung adenocarcinoma.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22327624","citation_count":673,"is_preprint":false},{"pmid":"24561444","id":"PMC_24561444","title":"RET revisited: expanding the oncogenic portfolio.","date":"2014","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24561444","citation_count":398,"is_preprint":false},{"pmid":"12114746","id":"PMC_12114746","title":"RET/PTC rearrangement in thyroid tumors.","date":"2002","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12114746","citation_count":355,"is_preprint":false},{"pmid":"3037315","id":"PMC_3037315","title":"ret transforming gene encodes a fusion protein homologous to tyrosine kinases.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3037315","citation_count":351,"is_preprint":false},{"pmid":"29912274","id":"PMC_29912274","title":"Selective RET kinase inhibition for patients with RET-altered cancers.","date":"2018","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29912274","citation_count":347,"is_preprint":false},{"pmid":"9182803","id":"PMC_9182803","title":"TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret.","date":"1997","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/9182803","citation_count":305,"is_preprint":false},{"pmid":"10458257","id":"PMC_10458257","title":"RET proto-oncogene in the development of human cancer.","date":"1999","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10458257","citation_count":263,"is_preprint":false},{"pmid":"11114739","id":"PMC_11114739","title":"The RET proto-oncogene in human cancers.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11114739","citation_count":242,"is_preprint":false},{"pmid":"11585664","id":"PMC_11585664","title":"The RET receptor: function in development and dysfunction in congenital malformation.","date":"2001","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/11585664","citation_count":234,"is_preprint":false},{"pmid":"31988000","id":"PMC_31988000","title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.","date":"2020","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31988000","citation_count":227,"is_preprint":false},{"pmid":"31715421","id":"PMC_31715421","title":"RET fusions in solid tumors.","date":"2019","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/31715421","citation_count":196,"is_preprint":false},{"pmid":"10652352","id":"PMC_10652352","title":"Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10652352","citation_count":186,"is_preprint":false},{"pmid":"19898483","id":"PMC_19898483","title":"Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19898483","citation_count":179,"is_preprint":false},{"pmid":"11707626","id":"PMC_11707626","title":"RET oncogene activation in papillary thyroid carcinoma.","date":"2001","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11707626","citation_count":155,"is_preprint":false},{"pmid":"15013219","id":"PMC_15013219","title":"RET and neuroendocrine tumors.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15013219","citation_count":151,"is_preprint":false},{"pmid":"8901418","id":"PMC_8901418","title":"RET mutations in human disease.","date":"1996","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/8901418","citation_count":147,"is_preprint":false},{"pmid":"15331579","id":"PMC_15331579","title":"Minireview: RET: normal and abnormal functions.","date":"2004","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15331579","citation_count":137,"is_preprint":false},{"pmid":"19934298","id":"PMC_19934298","title":"Targeting the RET pathway in thyroid cancer.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19934298","citation_count":135,"is_preprint":false},{"pmid":"34391699","id":"PMC_34391699","title":"Precision therapy for RET-altered cancers with RET inhibitors.","date":"2021","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34391699","citation_count":130,"is_preprint":false},{"pmid":"32094155","id":"PMC_32094155","title":"Advances in Targeting RET-Dependent Cancers.","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32094155","citation_count":122,"is_preprint":false},{"pmid":"8570194","id":"PMC_8570194","title":"RET activation by germline MEN2A and MEN2B mutations.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8570194","citation_count":121,"is_preprint":false},{"pmid":"12652644","id":"PMC_12652644","title":"RET and NTRK1 proto-oncogenes in human diseases.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12652644","citation_count":113,"is_preprint":false},{"pmid":"30446652","id":"PMC_30446652","title":"RET rearrangements are actionable alterations in breast cancer.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30446652","citation_count":103,"is_preprint":false},{"pmid":"25234288","id":"PMC_25234288","title":"Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/25234288","citation_count":102,"is_preprint":false},{"pmid":"35304457","id":"PMC_35304457","title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35304457","citation_count":100,"is_preprint":false},{"pmid":"32326537","id":"PMC_32326537","title":"RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32326537","citation_count":99,"is_preprint":false},{"pmid":"15240784","id":"PMC_15240784","title":"Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.","date":"2004","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/15240784","citation_count":99,"is_preprint":false},{"pmid":"24296167","id":"PMC_24296167","title":"Central role of RET in thyroid cancer.","date":"2013","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/24296167","citation_count":98,"is_preprint":false},{"pmid":"16979782","id":"PMC_16979782","title":"Current concepts in RET-related genetics, signaling and therapeutics.","date":"2006","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/16979782","citation_count":92,"is_preprint":false},{"pmid":"29284153","id":"PMC_29284153","title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/29284153","citation_count":89,"is_preprint":false},{"pmid":"9242375","id":"PMC_9242375","title":"Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9242375","citation_count":89,"is_preprint":false},{"pmid":"30069760","id":"PMC_30069760","title":"Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.","date":"2018","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30069760","citation_count":82,"is_preprint":false},{"pmid":"35957881","id":"PMC_35957881","title":"RET signaling pathway and RET inhibitors in human cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35957881","citation_count":79,"is_preprint":false},{"pmid":"21251878","id":"PMC_21251878","title":"RET in breast cancer: functional and therapeutic implications.","date":"2011","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21251878","citation_count":79,"is_preprint":false},{"pmid":"11536047","id":"PMC_11536047","title":"MEN2A-RET-induced cellular transformation by activation of STAT3.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11536047","citation_count":74,"is_preprint":false},{"pmid":"25731779","id":"PMC_25731779","title":"The RET oncogene in papillary thyroid carcinoma.","date":"2015","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25731779","citation_count":74,"is_preprint":false},{"pmid":"15548547","id":"PMC_15548547","title":"TTF-1 and RET promoter SNPs: regulation of RET transcription in Hirschsprung's disease.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15548547","citation_count":74,"is_preprint":false},{"pmid":"15583857","id":"PMC_15583857","title":"Dysfunction of the RET receptor in human cancer.","date":"2004","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/15583857","citation_count":69,"is_preprint":false},{"pmid":"26929027","id":"PMC_26929027","title":"A subpopulation of itch-sensing neurons marked by Ret and somatostatin expression.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26929027","citation_count":67,"is_preprint":false},{"pmid":"24756794","id":"PMC_24756794","title":"Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.","date":"2014","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24756794","citation_count":66,"is_preprint":false},{"pmid":"29018141","id":"PMC_29018141","title":"Vitamin D regulation of GDNF/Ret signaling in dopaminergic neurons.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29018141","citation_count":66,"is_preprint":false},{"pmid":"27496134","id":"PMC_27496134","title":"Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27496134","citation_count":66,"is_preprint":false},{"pmid":"9174404","id":"PMC_9174404","title":"RET in human development and oncogenesis.","date":"1997","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9174404","citation_count":63,"is_preprint":false},{"pmid":"25944708","id":"PMC_25944708","title":"Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25944708","citation_count":62,"is_preprint":false},{"pmid":"32816064","id":"PMC_32816064","title":"Intracellular RET signaling pathways activated by GDNF.","date":"2020","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/32816064","citation_count":58,"is_preprint":false},{"pmid":"12087092","id":"PMC_12087092","title":"Role of Dok1 in cell signaling mediated by RET tyrosine kinase.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12087092","citation_count":58,"is_preprint":false},{"pmid":"24022366","id":"PMC_24022366","title":"To bud or not to bud: the RET perspective in CAKUT.","date":"2014","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/24022366","citation_count":57,"is_preprint":false},{"pmid":"15316058","id":"PMC_15316058","title":"Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.","date":"2004","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/15316058","citation_count":57,"is_preprint":false},{"pmid":"10027007","id":"PMC_10027007","title":"Signal transduction by the receptor tyrosine kinase Ret.","date":"1998","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10027007","citation_count":56,"is_preprint":false},{"pmid":"17032739","id":"PMC_17032739","title":"Inhibition of RET tyrosine kinase by SU5416.","date":"2006","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17032739","citation_count":56,"is_preprint":false},{"pmid":"28615362","id":"PMC_28615362","title":"Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28615362","citation_count":54,"is_preprint":false},{"pmid":"9768676","id":"PMC_9768676","title":"RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9768676","citation_count":51,"is_preprint":false},{"pmid":"35756966","id":"PMC_35756966","title":"RET kinase inhibitors for RET-altered thyroid cancers.","date":"2022","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35756966","citation_count":49,"is_preprint":false},{"pmid":"33150251","id":"PMC_33150251","title":"Roles of the RET Proto-oncogene in Cancer and Development.","date":"2020","source":"JMA journal","url":"https://pubmed.ncbi.nlm.nih.gov/33150251","citation_count":49,"is_preprint":false},{"pmid":"14712226","id":"PMC_14712226","title":"The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14712226","citation_count":49,"is_preprint":false},{"pmid":"22875993","id":"PMC_22875993","title":"Alternative splicing results in RET isoforms with distinct trafficking properties.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22875993","citation_count":48,"is_preprint":false},{"pmid":"28609830","id":"PMC_28609830","title":"Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28609830","citation_count":48,"is_preprint":false},{"pmid":"27626672","id":"PMC_27626672","title":"Drosophila Cancer Models Identify Functional Differences between Ret Fusions.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27626672","citation_count":48,"is_preprint":false},{"pmid":"21110809","id":"PMC_21110809","title":"Development of RET kinase inhibitors for targeted cancer therapy.","date":"2011","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21110809","citation_count":45,"is_preprint":false},{"pmid":"28490466","id":"PMC_28490466","title":"RET Signaling in Prostate Cancer.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28490466","citation_count":44,"is_preprint":false},{"pmid":"25122427","id":"PMC_25122427","title":"RET mutation and expression in small-cell lung cancer.","date":"2014","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25122427","citation_count":44,"is_preprint":false},{"pmid":"8573606","id":"PMC_8573606","title":"Oncogenic activation of the ret protooncogene in thyroid cancer.","date":"1995","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8573606","citation_count":44,"is_preprint":false},{"pmid":"32461304","id":"PMC_32461304","title":"Targeting RET Kinase in Neuroendocrine Prostate Cancer.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32461304","citation_count":43,"is_preprint":false},{"pmid":"7563185","id":"PMC_7563185","title":"RET gene and its implications for cancer.","date":"1995","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/7563185","citation_count":43,"is_preprint":false},{"pmid":"10070972","id":"PMC_10070972","title":"Ret-mediated mitogenesis requires Src kinase activity.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10070972","citation_count":41,"is_preprint":false},{"pmid":"23400839","id":"PMC_23400839","title":"RET and NRG1 interplay in Hirschsprung disease.","date":"2013","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23400839","citation_count":41,"is_preprint":false},{"pmid":"11237712","id":"PMC_11237712","title":"Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11237712","citation_count":41,"is_preprint":false},{"pmid":"34493590","id":"PMC_34493590","title":"Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.","date":"2021","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34493590","citation_count":37,"is_preprint":false},{"pmid":"23461584","id":"PMC_23461584","title":"RET inhibition: implications in cancer therapy.","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23461584","citation_count":37,"is_preprint":false},{"pmid":"32737575","id":"PMC_32737575","title":"RET-independent signaling by GDNF ligands and GFRα receptors.","date":"2020","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/32737575","citation_count":35,"is_preprint":false},{"pmid":"27873490","id":"PMC_27873490","title":"EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.","date":"2017","source":"Yonsei medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27873490","citation_count":35,"is_preprint":false},{"pmid":"36632846","id":"PMC_36632846","title":"RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.","date":"2023","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36632846","citation_count":34,"is_preprint":false},{"pmid":"27872141","id":"PMC_27872141","title":"Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27872141","citation_count":34,"is_preprint":false},{"pmid":"12063395","id":"PMC_12063395","title":"Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12063395","citation_count":33,"is_preprint":false},{"pmid":"30853441","id":"PMC_30853441","title":"FAT4 Fine-Tunes Kidney Development by Regulating RET Signaling.","date":"2019","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/30853441","citation_count":32,"is_preprint":false},{"pmid":"23342255","id":"PMC_23342255","title":"RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.","date":"2012","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23342255","citation_count":32,"is_preprint":false},{"pmid":"17036197","id":"PMC_17036197","title":"RET and neuroendocrine tumors.","date":"2006","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/17036197","citation_count":30,"is_preprint":false},{"pmid":"7595167","id":"PMC_7595167","title":"The RET proto-oncogene and cancer.","date":"1995","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595167","citation_count":30,"is_preprint":false},{"pmid":"37743366","id":"PMC_37743366","title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37743366","citation_count":30,"is_preprint":false},{"pmid":"16448984","id":"PMC_16448984","title":"Molecular mechanisms of RET-induced Hirschsprung pathogenesis.","date":"2006","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16448984","citation_count":29,"is_preprint":false},{"pmid":"10838497","id":"PMC_10838497","title":"Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.","date":"2000","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10838497","citation_count":27,"is_preprint":false},{"pmid":"17916994","id":"PMC_17916994","title":"RET signaling in endocrine tumors: delving deeper into molecular mechanisms.","date":"2007","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17916994","citation_count":27,"is_preprint":false},{"pmid":"21450093","id":"PMC_21450093","title":"Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization.","date":"2011","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/21450093","citation_count":26,"is_preprint":false},{"pmid":"27402614","id":"PMC_27402614","title":"RET mutation and increased angiogenesis in medullary thyroid carcinomas.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27402614","citation_count":25,"is_preprint":false},{"pmid":"15231654","id":"PMC_15231654","title":"The RET receptor is linked to stress response pathways.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15231654","citation_count":24,"is_preprint":false},{"pmid":"35582449","id":"PMC_35582449","title":"RET kinase alterations in targeted cancer therapy.","date":"2020","source":"Cancer drug resistance (Alhambra, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35582449","citation_count":23,"is_preprint":false},{"pmid":"19057948","id":"PMC_19057948","title":"CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.","date":"2009","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19057948","citation_count":23,"is_preprint":false},{"pmid":"24821093","id":"PMC_24821093","title":"GM1 ganglioside enhances Ret signaling in striatum.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24821093","citation_count":23,"is_preprint":false},{"pmid":"38118420","id":"PMC_38118420","title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38118420","citation_count":22,"is_preprint":false},{"pmid":"20442138","id":"PMC_20442138","title":"The RET51/FKBP52 complex and its involvement in Parkinson disease.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20442138","citation_count":21,"is_preprint":false},{"pmid":"23056499","id":"PMC_23056499","title":"AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23056499","citation_count":20,"is_preprint":false},{"pmid":"8791480","id":"PMC_8791480","title":"RET oncogene.","date":"1996","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/8791480","citation_count":19,"is_preprint":false},{"pmid":"26304132","id":"PMC_26304132","title":"Distinct Temporal Regulation of RET Isoform Internalization: Roles of Clathrin and AP2.","date":"2015","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/26304132","citation_count":19,"is_preprint":false},{"pmid":"21357690","id":"PMC_21357690","title":"RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21357690","citation_count":19,"is_preprint":false},{"pmid":"26933947","id":"PMC_26933947","title":"miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26933947","citation_count":18,"is_preprint":false},{"pmid":"9126763","id":"PMC_9126763","title":"Altered RET gene mRNA expression in Hirschsprung's disease.","date":"1997","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/9126763","citation_count":18,"is_preprint":false},{"pmid":"37360768","id":"PMC_37360768","title":"Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers.","date":"2023","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37360768","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44795,"output_tokens":7167,"usd":0.120945,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16328,"output_tokens":7081,"usd":0.129332,"stage2_stop_reason":"end_turn"},"total_usd":0.250277,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"The RET transforming gene encodes a fusion protein with a carboxy-terminal domain homologous to tyrosine kinases (40-50% homology), preceded by a hydrophobic transmembrane domain sequence, establishing RET as a transmembrane receptor tyrosine kinase.\",\n      \"method\": \"cDNA cloning and sequencing of ret transforming gene\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing and structural characterization, foundational paper replicated across decades\",\n      \"pmids\": [\"3037315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MEN2A mutations in extracellular cysteine residues of RET result in constitutive RET dimerization and ligand-independent kinase activation, while the MEN2B mutation (M918T in the kinase domain) activates RET kinase constitutively without covalent dimerization but alters catalytic properties both quantitatively and qualitatively. Both convert RET into a dominant transforming gene in NIH 3T3 cells.\",\n      \"method\": \"NIH 3T3 transformation assay, biochemical analysis of RET dimerization and kinase activity, mutagenesis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, mutagenesis, transformation assay; replicated by multiple labs (PMID 8570194)\",\n      \"pmids\": [\"7824936\", \"8570194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GDNF signals through the Ret receptor tyrosine kinase: a Xenopus embryo bioassay demonstrated GDNF activates Ret, and explant cultures from Ret-deficient mouse embryos showed that normal Ret function is necessary for GDNF signaling in the peripheral nervous system, establishing Ret as a functional receptor for GDNF essential for kidney organogenesis and peripheral nervous system development.\",\n      \"method\": \"Xenopus embryo bioassay, Ret-knockout mouse explant cultures\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function (Ret-KO) combined with bioassay, replicated across multiple labs\",\n      \"pmids\": [\"8657282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TrnR2 (GFRα2) is a GPI-anchored co-receptor that mediates both neurturin and GDNF signaling through Ret. Fibroblasts expressing TrnR2 and Ret are ~30-fold more sensitive to neurturin than to GDNF, whereas TrnR1 (GFRα1)-Ret complexes respond equivalently to both, establishing that distinct GFRα-Ret complexes confer differential ligand selectivity.\",\n      \"method\": \"Receptor reconstitution in fibroblasts, cell-based signaling assay, expression analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution experiment with quantitative ligand sensitivity measurements, clear mechanistic distinction between co-receptor complexes\",\n      \"pmids\": [\"9182803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"FMTC mutations E768D and V804L in the RET kinase domain are gain-of-function mutations that confer autophosphorylation and transforming activity selectively to the RET51 long isoform (1114 aa) but not to the RET9 short isoform, demonstrating isoform-specific oncogenic activation and providing a biochemical basis for phenotype restriction to thyroid C-cells.\",\n      \"method\": \"Site-directed mutagenesis, autophosphorylation assay, Rat1 fibroblast transformation assay, PC12 neuronal differentiation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with multiple functional readouts (transformation, autophosphorylation, differentiation), clear isoform comparison\",\n      \"pmids\": [\"9242375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Ret stimulation activates c-Src kinase, and Ret associates with the SH2 domain of Src in a phosphotyrosine-dependent manner. Microinjection of a kinase-inactive c-Src mutant blocks Ret-mediated mitogenic effect, establishing that Src kinase activity is required for Ret-mediated mitogenesis.\",\n      \"method\": \"c-Src kinase activity assay, SH2 domain pull-down, microinjection of dominant-negative c-Src\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical interaction assay plus dominant-negative epistasis experiment, multiple orthogonal methods\",\n      \"pmids\": [\"10070972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MEN2A-RET (Cys634) activates PI3K and its downstream effector AKT/PKB. Mutation of Tyr-1062 (docking site for Shc and p85 regulatory subunit of PI3K) abrogates PI3K/AKT activation and abolishes transforming activity. A dominant-interfering PI3K suppresses RET-MEN2A transformation, while AKT overexpression enhances it, establishing PI3K/AKT as essential for RET-mediated transformation.\",\n      \"method\": \"PI3K activity assay, AKT phosphorylation assay, site-directed mutagenesis (Y1062F), retroviral dominant-negative PI3K expression, soft agar transformation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, kinase assays, dominant-negative epistasis, and transformation assay in single study with multiple orthogonal methods\",\n      \"pmids\": [\"10652352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MEN2A-RET activates STAT3 via two YxxV/Q STAT3 docking sites at Tyr752 and Tyr928, inducing both Tyr705 and Ser727 phosphorylation of STAT3. STAT3α (but not STAT3β) mediates enhanced proliferation and cyclin-D1 promoter activity downstream of MEN2A-RET, establishing STAT3 as a component of MEN2A-RET oncogenic signaling.\",\n      \"method\": \"Stable NIH3T3 cell lines, STAT3 phosphorylation assay, cyclin-D1 promoter reporter assay, soft agar growth assay, mutagenesis of docking sites\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based assays with reporter and phenotypic readouts, single lab with two orthogonal methods\",\n      \"pmids\": [\"11536047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"GDNF activates BMK1 (ERK5) through RET tyrosine kinase via phosphorylation of tyrosine 1062. BMK1 activation is not significantly impaired by MEK1 or PI3K inhibitors, indicating a distinct signaling pathway from Y1062. RET-MEN2A activates MEF2C transcription factor in a Y1062-dependent manner via MEK5.\",\n      \"method\": \"BMK1 kinase activation assay, Y1062F mutagenesis, pharmacological pathway inhibitors, luciferase reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis combined with pharmacological inhibitors and reporter assay, single lab\",\n      \"pmids\": [\"11237712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Dok1 is a docking protein for RET tyrosine kinase (identified by yeast two-hybrid). Dok1 binds RET-MEN2B more strongly than RET-MEN2A. Dok1 (via Ras-GAP binding at multiple tyrosines) suppresses Ras/Erk activation by GDNF/RET-MEN2B, while Dok1 (via Nck binding at Y361) is required for JNK/c-Jun activation, establishing Dok1 as a bifunctional scaffold with opposing effects on RET downstream pathways.\",\n      \"method\": \"Yeast two-hybrid screen, site-directed mutagenesis of Dok1 tyrosines, Ras/Erk and JNK/c-Jun activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — yeast two-hybrid identification confirmed by mutagenesis and multiple pathway assays, mechanistically detailed\",\n      \"pmids\": [\"12087092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Dominant-negative RET(ΔTK) disrupts oncogenic RET autophosphorylation in MTC cells, abolishing downstream Akt and ERK phosphorylation, decreasing cyclin D1 expression, increasing p21 and p27, stimulating apoptosis with decreased BCL-2, reducing cell cycle progression, and suppressing tumor growth in transgenic mice with orthotopic MTC.\",\n      \"method\": \"Adenoviral dominant-negative RET expression, Western blotting of signaling proteins, cell cycle analysis, apoptosis assay, in vivo transgenic mouse tumor model\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative loss-of-function with multiple downstream pathway readouts in vitro and in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"15316058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS transcription factors Etv4 and Etv5 are positively regulated downstream of GDNF-Ret signaling in ureteric bud tips. Double knockout mice lacking both Etv4 alleles and one Etv5 allele show renal agenesis or severe hypodysplasia; complete double homozygous knockout causes total kidney development failure. Downstream Etv4/Etv5 targets include Cxcr4, Myb, Met, and Mmp14, establishing Etv4/Etv5 as key effectors in the Ret-dependent gene network for renal branching morphogenesis.\",\n      \"method\": \"Genetic mouse knockouts (Etv4/Etv5 compound mutants), gene expression analysis in ureteric bud\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via compound knockout mice with clear organ-level phenotype and downstream gene identification\",\n      \"pmids\": [\"19898483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RET51 activation by GDNF or NGF triggers formation of a RET51/FKBP52 complex. Substitution of tyrosine 905 of RET51 (phosphorylated by both GDNF and NGF) disrupts this complex, establishing Y905 phosphorylation as required for RET51-FKBP52 interaction.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (Y905 substitution), patient mutation screening\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP with mutagenesis validation, single lab, mechanistically specific\",\n      \"pmids\": [\"20442138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Caspase cleavage of RET generates two fragments: an intracellular domain capable of triggering apoptosis, and a membrane-anchored N-terminal ectodomain (containing cadherin domains) that functions as a cadherin accessory protein, enhancing cadherin-mediated cell aggregation in sympathetic neurons. This establishes a non-canonical ligand-independent role for RET in cell adhesion regulation.\",\n      \"method\": \"Caspase cleavage assay, cell aggregation assay in sympathetic neurons, mutagenesis of caspase cleavage site\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical cleavage assay plus functional cell adhesion readout, single lab with two orthogonal approaches\",\n      \"pmids\": [\"21357690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RET is alternatively spliced to encode isoforms (primarily RET9 and RET51) with distinct trafficking properties: RET9 accumulates in the Golgi intracellularly while RET51 is efficiently matured and present at higher levels on the plasma membrane. RET51 is internalized faster after ligand binding and undergoes recycling back to the plasma membrane. This differential trafficking produces more rapid and longer ERK/MAPK signaling from RET51 versus RET9.\",\n      \"method\": \"Subcellular fractionation, live-cell imaging, FRAP, internalization assays, ERK/MAPK signaling time-course\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal localization and trafficking methods (fractionation, live imaging, FRAP) directly linked to functional signaling differences\",\n      \"pmids\": [\"22875993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIF5B-RET fusion leads to aberrant constitutive activation of RET kinase and functions as an oncogenic driver in lung adenocarcinoma, as demonstrated by anchorage-independent growth of NIH3T3 cells that is suppressible by the RET tyrosine kinase inhibitor vandetanib.\",\n      \"method\": \"Whole-transcriptome sequencing to identify fusion, NIH3T3 transformation assay, RET kinase inhibitor treatment\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional transformation assay with pharmacological validation, replicated in two independent papers (PMID 22327623 and 22327624)\",\n      \"pmids\": [\"22327624\", \"22327623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GM1 ganglioside enhances Ret kinase activity in striatal tissue via GFRα1, increasing binding of endogenous GDNF to GFRα1. GM1-induced Ret activation leads to Tyr1062 phosphorylation and PI3K/Akt and Erk and Src signaling recruitment. Src kinase (PP1/PP2 sensitive) is required for GM1-induced Ret activation. Neutralization of released GDNF does not inhibit the Ret response, indicating GM1 acts upstream at the GFRα1 level.\",\n      \"method\": \"Striatal slice preparation, kinase activity assay, Src inhibitor treatment, GDNF neutralization, co-receptor dependence assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitors plus neutralization experiment in tissue preparation, single lab\",\n      \"pmids\": [\"24821093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RET internalization occurs primarily through clathrin-coated pits (not caveolin). The AP2 μ subunit interacts directly with both RET isoforms and is required for RET internalization via clathrin-mediated endocytosis. RET51 is rapidly and robustly recruited to clathrin-coated pits upon GDNF stimulation, while RET9 recruitment is slower and less pronounced, contributing to their distinct signaling durations.\",\n      \"method\": \"TIRF microscopy, co-localization with clathrin/caveolin, AP2 interaction assay, siRNA knockdown of AP2\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — TIRF live imaging combined with AP2 interaction assay and functional knockdown, multiple orthogonal methods in single study\",\n      \"pmids\": [\"26304132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RET51 isoform depletion has significantly greater effects than RET9 depletion on medullary thyroid carcinoma (MTC) cell survival, proliferation, anoikis resistance, and on papillary thyroid carcinoma (PTC) cell migration, mesenchymal marker expression, matrix metalloproteinase expression, and invasive potential, establishing RET51 as the functionally dominant isoform in thyroid carcinoma contexts.\",\n      \"method\": \"shRNA-mediated isoform-specific knockdown, cell viability assay, migration assay, invasion assay, anoikis assay, immunoblotting of EMT markers\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific KD with multiple functional readouts, single lab\",\n      \"pmids\": [\"27872141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Drosophila models of CCDC6-RET and NCOA4-RET fusions show that both drive cell migration, delamination, and EMT, but NCOA4-RET produces more severe phenotypes than CCDC6-RET mirroring clinical behavior. A kinome/drug screen revealed CCDC6-RET and NCOA4-RET act through different signaling networks with distinct drug sensitivities, and WEE1 inhibitor plus sorafenib is synergistically specific for NCOA4-RET.\",\n      \"method\": \"Drosophila transgenic cancer model, kinome RNAi screen, drug library screen, combination drug synergy assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic screen in Drosophila model with pharmacological validation, single lab\",\n      \"pmids\": [\"27626672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Potent RET inhibitors (AD80, ponatinib) that bind RET in the DFG-out (catalytically inactive) conformation selectively kill RET-rearranged tumor cells. Chemical genomics and phosphoproteomics identified the CCDC6-RET I788N mutation and MAPK pathway reactivation as resistance mechanisms to RET inhibitors.\",\n      \"method\": \"DFG-out conformation binding (type II inhibitors), chemical genomics screen, phosphoproteomics in RET-rearranged cells, drug sensitivity assays\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural binding mode characterization combined with phosphoproteomics and resistance mechanism identification, multiple orthogonal methods\",\n      \"pmids\": [\"28615362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FAT4 (atypical cadherin) interacts with RET through extracellular cadherin repeats and perturbs assembly of the RET-GFRα1-GDNF signaling complex, reducing RET signaling. Loss of Fat4 in mice causes excessive RET signaling and abnormal ureteric budding; removing one copy of Gdnf rescues the Fat4-knockout kidney phenotype, establishing FAT4 as a juxtacrine negative regulator of RET signaling during kidney development.\",\n      \"method\": \"Fat4 conditional knockout mice, Gdnf genetic rescue experiment, co-immunoprecipitation of FAT4-RET interaction, kidney developmental analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Gdnf heterozygous rescue of Fat4 KO) plus biochemical interaction (Co-IP), multiple orthogonal methods\",\n      \"pmids\": [\"30853441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Acquired resistance to selpercatinib (selective RET inhibitor) is driven by RET G810 solvent front mutations (G810R, G810S, G810C) that sterically hinder selpercatinib binding, as predicted by structural modeling and confirmed by in vitro kinase and cell-based assays. In addition, MET amplification and rare RET-wildtype tumor cell populations driven by alternative mitogenic drivers represent off-target resistance routes.\",\n      \"method\": \"Circulating tumor DNA analysis, post-mortem biopsy, patient-derived xenograft model of acquired resistance, enzyme assay, cell-based assay, structural modeling\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clinical ctDNA and tissue combined with in vitro enzyme/cell assays and structural modeling; replicated in multiple patients and labs (PMID 31988000, 35304457)\",\n      \"pmids\": [\"31988000\", \"35304457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Vepafestinib (TAS0953/HM06) has a unique binding mode to RET with best-in-class selectivity, retains activity against RETL730, RETV804, and RETG810 on-target resistance mutations, and shows superior CNS pharmacokinetics compared to approved RET inhibitors, translating to improved tumor control in an intracranial RET-driven cancer model.\",\n      \"method\": \"In vitro RET kinase selectivity panel, cell-based assays with resistance mutants, pharmacokinetic brain penetration studies, intracranial xenograft model\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and in vivo methods in single study, single lab, novel binding mode claimed but full structural detail not described in abstract\",\n      \"pmids\": [\"37743366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"EGF/EGFR activation triggers resistance to RET inhibitors (sunitinib, E7080, vandetanib, sorafenib) in CCDC6-RET lung cancer cells by transducing bypass survival signaling through ERK and AKT. EGFR-TKI treatment resensitizes cells to RET inhibitors, establishing EGFR bypass as a mechanism of RET inhibitor resistance.\",\n      \"method\": \"Cell viability assay with RET inhibitors ± EGF, ERK/AKT phosphorylation Western blot, EGFR siRNA, EGFR-TKI combination\",\n      \"journal\": \"Yonsei medical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown and pharmacological rescue in cell lines, single lab\",\n      \"pmids\": [\"27873490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TTF-1 (thyroid transcription factor-1) directly binds the RET promoter and activates RET transcription. HSCR-associated RET promoter SNPs overlap TTF-1 binding sites and decrease RET transcription in functional reporter assays. A TTF-1 missense mutation (Gly322Ser) in an HSCR patient compromises activation from HSCR-associated RET promoter haplotypes, establishing TTF-1 as a direct transcriptional regulator of RET.\",\n      \"method\": \"Luciferase reporter assay, TTF-1 binding site analysis, patient mutation functional characterization, chromatin context analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter reporter assay combined with patient mutation functional characterization, single lab\",\n      \"pmids\": [\"15548547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDNF plus GFRα1 (but not GDNF alone) promotes RET-dependent perineural invasion, proliferation, and soft agar colony formation in prostate cancer cells. Conditioned medium from dorsal root ganglia (containing secreted GFRα1) promotes these transformed phenotypes, blocked by anti-GFRα1 antibody. RET signaling activates ERK or AKT depending on context, but p70S6 kinase phosphorylation is markedly increased in all cases; p70S6K knockdown markedly decreases RET-induced transformed phenotypes.\",\n      \"method\": \"RET knockdown, anti-GFRα1 antibody, dorsal root ganglion perineural invasion assay, p70S6K siRNA, Western blotting, in vivo tumor xenograft\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown of RET and p70S6K with multiple functional readouts, in vivo xenograft, single lab\",\n      \"pmids\": [\"28490466\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RET is a single-pass transmembrane receptor tyrosine kinase that requires GPI-anchored GFRα co-receptors to bind GDNF family ligands, upon which it dimerizes and trans-autophosphorylates specific intracellular tyrosines (notably Y1062) to recruit adaptor proteins (Shc, Dok1, p85-PI3K) activating RAS/ERK, PI3K/AKT, JNK, STAT3, and BMK1/ERK5 pathways; oncogenic activation occurs either through extracellular cysteine mutations (MEN2A) that force constitutive disulfide-bonded dimerization, or through kinase-domain mutations (MEN2B M918T) that alter catalytic specificity without covalent dimerization, or through chromosomal rearrangements (RET/PTC, KIF5B-RET, CCDC6-RET, NCOA4-RET) that replace the extracellular domain with dimerization-promoting partner sequences; two major C-terminal splice isoforms, RET9 and RET51, display distinct Golgi retention versus plasma membrane localization, differential clathrin/AP2-mediated internalization kinetics, and consequently different ERK/MAPK signaling durations, with RET51 being the functionally dominant isoform; acquired resistance to selective RET inhibitors (selpercatinib) is primarily driven by solvent-front mutations at G810 that sterically block inhibitor binding, and by MAPK pathway reactivation through MET amplification or alternative driver selection.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RET is a single-pass transmembrane receptor tyrosine kinase that transduces signals from GDNF-family ligands to control kidney organogenesis and peripheral nervous system development [#0, #2]. Ligand recognition is indirect: RET partners with GPI-anchored GFRα co-receptors, and the specific GFRα paralog assembled into the complex dictates ligand selectivity (GFRα1-RET responds to GDNF and neurturin equivalently, while GFRα2-RET is biased toward neurturin) [#3]. Upon ligand engagement RET trans-autophosphorylates intracellular tyrosines that serve as docking sites for adaptor and effector proteins, most prominently Y1062, which couples RET to PI3K/AKT and to the ERK5/BMK1-MEF2C axis [#6, #8]; additional sites recruit STAT3 (Y752/Y928), the bifunctional Dok1 scaffold that oppositely tunes Ras/ERK versus JNK output, and FKBP52 (Y905), while RET activation also engages c-Src kinase as a required mediator of mitogenesis [#5, #7, #9, #12]. In renal development this signaling drives a branching-morphogenesis gene network through the ETS transcription factors Etv4/Etv5 and is held in check by the atypical cadherin FAT4, a juxtacrine negative regulator that perturbs RET-GFRα1-GDNF complex assembly [#11, #21]; RET transcription itself is directly activated by TTF-1 [#25]. RET is alternatively spliced into RET9 and RET51 isoforms with distinct trafficking — RET9 accumulates in the Golgi whereas RET51 matures efficiently to the plasma membrane, is more rapidly recruited to clathrin/AP2-coated pits and recycled, producing faster and longer ERK/MAPK signaling, and is the functionally dominant isoform in thyroid carcinoma [#14, #17, #18]. Oncogenic activation occurs through extracellular cysteine mutations (MEN2A) that force constitutive disulfide-bonded dimerization, kinase-domain mutations (MEN2B M918T) that constitutively activate and alter catalytic specificity without covalent dimerization, and chromosomal fusions (KIF5B-RET, CCDC6-RET, NCOA4-RET) that confer ligand-independent kinase activation and drive transformation, migration and EMT [#1, #15, #19]. RET is essential for tumor maintenance in these contexts, and inhibition reverses oncogenic signaling and tumor growth [#10]. Acquired resistance to selective RET inhibitors arises from G810 solvent-front mutations that sterically block drug binding and from bypass MAPK reactivation via MET amplification or EGFR signaling, motivating next-generation inhibitors that retain activity against resistance mutants [#20, #22, #24, #23]. Beyond canonical signaling, caspase cleavage generates a RET ectodomain that acts as a cadherin accessory protein promoting cell aggregation, a ligand-independent adhesion role [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established the molecular identity of RET as a transmembrane receptor tyrosine kinase, defining the protein class whose dysregulation underlies its oncogenic and developmental roles.\",\n      \"evidence\": \"cDNA cloning and sequencing of the ret transforming gene\",\n      \"pmids\": [\"3037315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the physiological ligand or co-receptor\", \"No downstream signaling characterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified GDNF as the activating ligand and demonstrated RET is genetically required for kidney and peripheral nervous system development, linking RET signaling to organogenesis.\",\n      \"evidence\": \"Xenopus embryo bioassay and Ret-knockout mouse explant cultures\",\n      \"pmids\": [\"8657282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ligand binding (co-receptor requirement) not yet defined\", \"Downstream effectors of developmental signaling unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved how RET achieves ligand selectivity, showing that distinct GPI-anchored GFRα co-receptors set the ligand preference of the RET complex.\",\n      \"evidence\": \"Receptor reconstitution in fibroblasts with quantitative ligand sensitivity measurements\",\n      \"pmids\": [\"9182803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of GFRα-RET-ligand assembly not resolved\", \"In vivo consequences of co-receptor switching not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined two mechanistically distinct routes to oncogenic RET activation — extracellular cysteine mutations forcing dimerization versus a kinase-domain mutation altering catalytic specificity — explaining MEN2A versus MEN2B.\",\n      \"evidence\": \"NIH 3T3 transformation assay, dimerization and kinase activity biochemistry, mutagenesis\",\n      \"pmids\": [\"7824936\", \"8570194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map full set of downstream effectors driving transformation\", \"Tissue specificity of phenotypes not explained\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed that oncogenic activation can be isoform-restricted, with FMTC kinase-domain mutations transforming RET51 but not RET9, providing a biochemical basis for tissue-restricted phenotypes.\",\n      \"evidence\": \"Site-directed mutagenesis with autophosphorylation, fibroblast transformation, and PC12 differentiation assays\",\n      \"pmids\": [\"9242375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular reason for differential isoform sensitivity not defined\", \"In vivo relevance to C-cell restriction inferred but not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified c-Src as a required effector of RET mitogenic signaling, extending the RET pathway beyond canonical adaptor recruitment.\",\n      \"evidence\": \"Src kinase activity assay, SH2 pull-down, and dominant-negative Src microinjection\",\n      \"pmids\": [\"10070972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RET tyrosine docking site for Src not mapped\", \"Relationship to other RET pathways not integrated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Pinpointed Y1062 as the docking site coupling RET to PI3K/AKT and demonstrated this axis is essential for RET-driven transformation.\",\n      \"evidence\": \"PI3K/AKT kinase assays, Y1062F mutagenesis, dominant-negative PI3K, soft agar transformation\",\n      \"pmids\": [\"10652352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate AKT from other Y1062-dependent outputs\", \"In vivo tumor dependence not tested in this study\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Expanded the RET signaling map to STAT3 (via Y752/Y928) and ERK5/BMK1-MEF2C (via Y1062), defining additional proliferative and transcriptional outputs.\",\n      \"evidence\": \"Cell-line phosphorylation assays, docking-site mutagenesis, and luciferase/cyclin-D1 reporter assays\",\n      \"pmids\": [\"11536047\", \"11237712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell-based evidence without in vivo confirmation\", \"Crosstalk between these parallel pathways not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Characterized Dok1 as a bifunctional RET scaffold that simultaneously suppresses Ras/ERK and enables JNK/c-Jun, revealing how a single adaptor can balance opposing RET outputs.\",\n      \"evidence\": \"Yeast two-hybrid identification with Dok1 tyrosine mutagenesis and pathway activation assays\",\n      \"pmids\": [\"12087092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequences of Dok1 balancing in normal development not tested\", \"Preferential MEN2B binding mechanism not structurally explained\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated that RET kinase activity is required for medullary thyroid carcinoma maintenance, validating RET as a therapeutic target in vivo.\",\n      \"evidence\": \"Adenoviral dominant-negative RET in MTC cells and transgenic orthotopic mouse tumor model with signaling, cell cycle, and apoptosis readouts\",\n      \"pmids\": [\"15316058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test small-molecule inhibition\", \"Effector(s) most critical for survival not isolated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified TTF-1 as a direct transcriptional activator of RET and linked HSCR-associated promoter variants to reduced RET expression, connecting RET dosage to disease.\",\n      \"evidence\": \"Luciferase reporter assays, TTF-1 binding site analysis, and functional characterization of a patient TTF-1 mutation\",\n      \"pmids\": [\"15548547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab reporter-based evidence\", \"Endogenous chromatin occupancy not directly shown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed Etv4/Etv5 as essential downstream effectors of GDNF-Ret signaling in renal branching morphogenesis, identifying the transcriptional output of the developmental pathway.\",\n      \"evidence\": \"Compound Etv4/Etv5 knockout mice with ureteric bud gene expression analysis\",\n      \"pmids\": [\"19898483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect regulation of target genes not fully separated\", \"How RET kinase output converts to Etv induction not mechanistically traced\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped a RET51-specific phosphotyrosine (Y905) required for FKBP52 recruitment, adding an isoform-selective interaction to the RET signaling repertoire.\",\n      \"evidence\": \"Co-immunoprecipitation with Y905 mutagenesis and patient mutation screening\",\n      \"pmids\": [\"20442138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP-based interaction without reciprocal structural validation\", \"Functional consequence of the RET51-FKBP52 complex not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Uncovered a non-canonical, ligand-independent RET function in which caspase cleavage yields an ectodomain acting as a cadherin accessory protein in cell adhesion.\",\n      \"evidence\": \"Caspase cleavage and cleavage-site mutagenesis assays with sympathetic neuron aggregation assays\",\n      \"pmids\": [\"21357690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab evidence; in vivo relevance not established\", \"Physiological trigger for caspase cleavage of RET unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked RET9/RET51 splice isoforms to distinct trafficking itineraries and signaling kinetics, explaining how isoform choice tunes the duration of ERK/MAPK output.\",\n      \"evidence\": \"Subcellular fractionation, live-cell imaging, FRAP, internalization assays, and ERK/MAPK time-courses\",\n      \"pmids\": [\"22875993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking machinery not yet identified at this stage\", \"Consequences for in vivo physiology not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established RET gene fusion (KIF5B-RET) as an oncogenic driver in lung adenocarcinoma, extending the spectrum of RET activation beyond point mutations.\",\n      \"evidence\": \"Whole-transcriptome sequencing, NIH3T3 transformation assay, and vandetanib inhibition\",\n      \"pmids\": [\"22327624\", \"22327623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not detail downstream signaling differences from other fusions\", \"Patient response data not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified clathrin/AP2-mediated endocytosis as the route of RET internalization and showed faster RET51 recruitment to coated pits underlies isoform-specific signaling durations.\",\n      \"evidence\": \"TIRF microscopy, AP2 μ-subunit interaction assay, and AP2 siRNA knockdown\",\n      \"pmids\": [\"26304132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream sorting fate (degradation versus recycling) not fully resolved here\", \"How endocytic rate quantitatively sets signal duration not modeled\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated RET51 is the functionally dominant isoform driving thyroid carcinoma survival, proliferation, migration and invasion, prioritizing it as the disease-relevant species.\",\n      \"evidence\": \"Isoform-specific shRNA knockdown with viability, migration, invasion, anoikis, and EMT-marker readouts\",\n      \"pmids\": [\"27872141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Mechanistic basis of isoform dominance in these phenotypes not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that different RET fusion partners (CCDC6-RET vs NCOA4-RET) signal through distinct networks with divergent drug sensitivities, revealing fusion-specific therapeutic vulnerabilities.\",\n      \"evidence\": \"Drosophila transgenic cancer models with kinome RNAi and drug-combination synergy screens\",\n      \"pmids\": [\"27626672\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Findings in Drosophila model require human validation\", \"Molecular basis for partner-specific signaling networks not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined DFG-out (type II) inhibitor binding as an effective strategy against RET-rearranged tumors and identified MAPK reactivation and a gatekeeper-region mutation as resistance routes.\",\n      \"evidence\": \"DFG-out inhibitor characterization, chemical genomics, and phosphoproteomics in RET-rearranged cells\",\n      \"pmids\": [\"28615362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not anticipate solvent-front resistance to selective inhibitors\", \"Clinical durability of type II inhibitors not assessed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established EGFR bypass signaling through ERK and AKT as a resistance mechanism to RET inhibitors that is reversible by EGFR-TKI co-treatment, defining an actionable combination strategy.\",\n      \"evidence\": \"Cell viability with RET inhibitors ± EGF, EGFR siRNA, and EGFR-TKI combination in CCDC6-RET lung cells\",\n      \"pmids\": [\"27873490\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell-line evidence\", \"In vivo and clinical relevance of the combination not tested here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed that secreted GFRα1 enables ligand-driven RET transformation and perineural invasion in prostate cancer, with p70S6K as a convergent required effector, extending RET oncogenic biology beyond mutation/fusion.\",\n      \"evidence\": \"RET and p70S6K knockdown, anti-GFRα1 antibody, dorsal root ganglion perineural invasion assay, and xenografts\",\n      \"pmids\": [\"28490466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Source and regulation of tumor-microenvironment GFRα1 not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified FAT4 as a juxtacrine negative regulator that restrains RET signaling during kidney development by perturbing RET-GFRα1-GDNF complex assembly.\",\n      \"evidence\": \"Fat4 conditional knockout mice with Gdnf heterozygous genetic rescue and FAT4-RET co-immunoprecipitation\",\n      \"pmids\": [\"30853441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of FAT4 interference with complex assembly not resolved\", \"Role outside kidney development not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the molecular basis of acquired resistance to selective RET inhibitor selpercatinib, identifying G810 solvent-front mutations and off-target MET amplification.\",\n      \"evidence\": \"ctDNA and post-mortem tissue analysis, patient-derived xenografts, kinase/cell-based assays, and structural modeling\",\n      \"pmids\": [\"31988000\", \"35304457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Strategies to overcome G810 mutations not provided in this study\", \"Frequency and co-occurrence of resistance routes not fully quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a next-generation RET inhibitor (vepafestinib) that retains activity against on-target resistance mutations and improves CNS penetration, addressing the resistance liabilities of prior inhibitors.\",\n      \"evidence\": \"RET kinase selectivity panel, resistance-mutant cell assays, brain-penetration pharmacokinetics, and intracranial xenograft model\",\n      \"pmids\": [\"37743366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-study; clinical efficacy not yet established\", \"Full structural basis of the unique binding mode not detailed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse RET tyrosine docking codes, isoform trafficking, and fusion-partner-specific networks integrate to produce context-specific physiological versus oncogenic outcomes remains incompletely resolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking phospho-site usage to pathway selection across cell types\", \"Predictive rules for which resistance route emerges under each inhibitor are lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [6, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [14, 17]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 15, 22]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [14, 17]}\n    ],\n    \"complexes\": [\"RET-GFRα1-GDNF signaling complex\"],\n    \"partners\": [\"GFRA1\", \"GFRA2\", \"GDNF\", \"SRC\", \"DOK1\", \"FKBP52\", \"AP2M1\", \"FAT4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}